Peter Kolchinsky's Net Worth

$1.96 Billion

Estimate Recalculated Feb 28, 2024 09:11PM EST

Who is Peter Kolchinsky?

Peter Kolchinsky has an estimated net worth of $1.96 Billion. This is based on reported shares across multiple companies, which include AN2 Therapeutics, Inc., RHYTHM PHARMACEUTICALS, INC., Vaxcyte, Inc., Dicerna Pharmaceuticals Inc, Eidos Therapeutics, Inc., iTeos Therapeutics, Inc., Mineralys Therapeutics, Inc., Cytek Biosciences, Inc., PMV Pharmaceuticals, Inc., Nkarta, Inc., DICE Therapeutics, Inc., SANGAMO BIOSCIENCES INC, Icosavax, Inc., Tyra Biosciences, Inc., MIRAGEN THERAPEUTICS, INC., Inhibrx, Inc., RxSight, Inc., Phathom Pharmaceuticals, Inc., Dyne Therapeutics, Inc., TG THERAPEUTICS, INC., Aclaris Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Eliem Therapeutics, Inc., KalVista Pharmaceuticals, Inc., Vor Biopharma Inc., Verastem, Inc., Janux Therapeutics, Inc., Aerovate Therapeutics, Inc., Research Alliance Corp. II, Forma Therapeutics Holdings, Inc., Therapeutics Acquisition Corp., G1 Therapeutics, Inc., ARVINAS INC., Synthorx, Inc., CURIS INC, Acumen Pharmaceuticals, Inc., 89bio, Inc., Solid Biosciences Inc., Inozyme Pharma, Inc., Pandion Therapeutics, Inc., Iterum Therapeutics plc, Kala Pharmaceuticals, Inc., Orchard Therapeutics plc, scPharmaceuticals Inc., Satsuma Pharmaceuticals, Inc., Akouos, Inc., Cardiff Oncology, Inc., Wave Life Sciences Ltd., Werewolf Therapeutics, Inc., Enliven Therapeutics, Inc., Ra Pharmaceuticals, Inc., Fulcrum Therapeutics, Inc., ACHILLION PHARMACEUTICALS INC, ARS Pharmaceuticals, Inc., PepGen Inc., Black Diamond Therapeutics, Inc., DERMA SCIENCES, INC., SEQUENOM INC, BIOSPECIFICS TECHNOLOGIES CORP, Acrivon Therapeutics, Inc., ARADIGM CORP, and LIPID SCIENCES INC/.

SEC CIK

Peter Kolchinsky's CIK is 0001384859

Past Insider Trading and Trends

2008 was Peter Kolchinsky's most active year for acquiring shares with 337 total transactions. Peter Kolchinsky's most active month to acquire stocks was the month of May. 2014 was Peter Kolchinsky's most active year for disposing of shares, totalling 164 transactions. Peter Kolchinsky's most active month to dispose stocks was the month of August. 2020 saw Peter Kolchinsky paying a total of $343,239,212.72 for 42,638,996 shares, this is the most they've acquired in one year. In 2020 Peter Kolchinsky cashed out on 119,531,075 shares for a total of $944,511,487.90, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

AN2 Therapeutics, Inc. (ANTX) Snapshot price: $19.9775

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+52.94%
1.78M
$9.00
$16,000,002.00
5.14M
Aug 18
Form 4
+0.03%
1.91K
$7.74
$14,330.32
7.55M
Aug 3 - Aug 4
Form 4
+0.62%
23.22K
$7.78
$180,674.69
3.77M
Jul 26 - Jul 27
Form 4
+0.01%
302
$7.99
$2,412.98
3.75M
Jun 21
Form 4
+2.22%
81.42K
$7.95
$647,401.86
3.75M
Jun 13 - Jun 14
Form 4
3.67M
$15.00
3.67M
Mar 29
Form 3
0
0
No matching records found

RHYTHM PHARMACEUTICALS, INC. (RYTM) Snapshot price: $47.83

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-5.19%
-238.54K
$29.47
-$7,029,652.62
4.36M
Dec 2 - Dec 3
Form 4
-2.50%
-131.58K
$22.06
-$2,902,517.12
5.14M
Jun 30 - Jul 2
Form 4
-2.77%
-150.32K
$23.05
-$3,465,614.60
5.27M
Jun 25 - Jun 29
Form 3
0
0
No matching records found

Vaxcyte, Inc. (PCVX) Snapshot price: $73.96

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-5.05%
-266.26K
$50.78
-$13,521,592.46
5M
Oct 7 - Oct 8
Form 4
-3.94%
-221.33K
$49.81
-$11,245,562.88
5.39M
Sep 29 - Oct 1
Form 3
0
0
No matching records found

Dicerna Pharmaceuticals Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-643.88K
$24.28
-$15,633,626.51
0
Nov 27 - Dec 2
Form 4
-55.36%
-798.60K
$23.53
-$18,794,613.99
643.88K
Nov 22 - Nov 26
Form 4
-41.28%
-1.01M
$23.34
-$23,667,124.03
1.44M
Nov 19 - Nov 21
Form 4
0
0
Jun 20
Form 4
-12.72%
-357.92K
$14.78
-$5,288,730.41
2.46M
Nov 7 - Nov 8
Form 4
-15.35%
-510.40K
$13.59
-$6,935,820.24
2.81M
Nov 2 - Nov 6
Form 4
-15.47%
-608.50K
$13.60
-$8,275,641.53
3.32M
Oct 30 - Nov 1
Form 4
0
0
Jun 21
Form 4
-1.39%
-55.30K
$11.05
-$611,125.83
3.93M
Mar 23
Form 4
-10.61%
-473.52K
$11.51
-$5,447,969.50
3.99M
Mar 19 - Mar 21
Form 4
-5.92%
-280.60K
$9.30
-$2,610,838.73
4.46M
Jan 17 - Jan 18
Form 4
-1.97%
-95.50K
$9.19
-$877,454.13
4.74M
Jan 4 - Jan 5
Form 4
-4.64%
-235.60K
$9.25
-$2,178,761.35
4.84M
Dec 29 - Jan 3
Form 4
+108.93%
2.65M
5.07M
Dec 18
Form 4
0
0
Jul 18
Form 4
0
0
Apr 11
Form 4
0
0
Jun 14
Form 4
0
0
Jun 25
Form 4
0
0
Jun 18
Form 4/A
0
0
Apr 16
Form 4
0
0
Apr 16
Form 4
2.43M
$15.00
2.43M
Feb 4
Form 3
0
0
No matching records found

Eidos Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.16M
$17.00
2.16M
Jun 22
Form 3
0
0
No matching records found